Key result
The MiTiHeart LVAD demonstrated efficacy in in vitro and in vivo calf model testing, confirming that native heart pulsatility does not adversely affect pump performance.
The MiTiHeart LVAD demonstrated promising in vitro and in vivo performance in a calf model, supporting its potential development for destination therapy in smaller adult heart failure patients.
The MiTiHeart (MiTiHeart Corporation, Gaithersburg, MD, USA) left ventricular assist device (LVAD), a third-generation blood pump, is being developed for destination therapy for adult heart failure patients of small to medium frame that are not being served by present pulsatile devices. The pump design is based on a novel, patented, hybrid passive/active magnetic bearing system with backup hydrodynamic thrust bearing and exhibits low power loss, low vibration, and low hemolysis. Performance of the titanium alloy prototype was evaluated in a series of in vitro tests with blood analogue to map out the performance envelop of the pump. The LVAD prototype was implanted in a calf animal model, and the in vivo pump performance was evaluated. The animal's native heart imparted a strong pulsatility to the flow rate. These tests confirmed the efficacy of the MiTiHeart LVAD design and confirmed that the pulsatility does not adversely affect the pump performance.
No takes yet. Share an insight, caveat, or question.
Jahanmir et al. (2008) studied Heart failure. MiTiHeart left ventricular assist device (LVAD) was evaluated on Pump performance and efficacy. The MiTiHeart LVAD demonstrated efficacy in in vitro and in vivo calf model testing, confirming that native heart pulsatility does not adversely affect pump performance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: